C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study

BACKGROUND: Poor response to anti-tumour necrosis factor biologicals like infliximab (IFX) is observed in patients with ulcerative colitis (UC), which may lead to prolonged morbidity and waste of medical resources. We aimed to look for potential biomarkers of response to IFX in patients with UC who...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasa, Ryota, Yamada, Akihiro, Sono, Koji, Furukawa, Ryuichi, Takeuchi, Ken, Suzuki, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535387/
https://www.ncbi.nlm.nih.gov/pubmed/26271624
http://dx.doi.org/10.1186/s12876-015-0333-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535387/
https://www.ncbi.nlm.nih.gov/pubmed/26271624
http://dx.doi.org/10.1186/s12876-015-0333-z

Ejemplares similares